Cellonis' Cell Treatment for Glioma May Prevent Tumor Recurrence and Improve Quality of Life Significantly

By Cellonis Biotechnologies Co. Ltd., PRNE
Tuesday, November 2, 2010

BEIJING, November 3, 2010 - "For brain cancer patients after surgery, the combined DC-CIK and stem
cell therapy from Cellonis Biotechnologies can be a very effective method in
preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.
"This is a new hope for cancer patients."

The unique therapy combines the latest stem cell and immuno technology
with the benefits of Traditional Chinese Medicine. Inger Marie Olsen from
Norway has recently concluded a cycle of the treatment in Beijing, and she
has been in a stable condition since the first cycle in September 2009.

Dr. Li has been guiding the treatment of Inger. "Inger's
general condition has improved very much," he remarks. "She can now speak,
move, eat and sleep much better, she has improved a great deal. I think her
quality of life is almost back to normal."

"I was diagnosed with cancer in 2005," Inger explains in a recent
interview. "I had chemotherapy, radiotherapy and three surgeries, but the
cancer still came back. A friend of mine read about this new therapy on the
internet and the people of my town arranged a fund to help me come here."

The Cellonis cancer therapy combines the latest research into cancer stem
cells with the advantages of Traditional Chinese Medicine to create a unique
cancer treatment. Dendritic cells, cultured and processed from blood taken
from the patient's body, are loaded with glioma stem cell antigens to create
a vaccine that can activate the immune system to kill cancer cells as well as
the cancer stem cells responsible for tumor initiation and recurrence.
Another patient like Inger with glioma who undertook the treatment earlier
this year, Mr. Guy Spavold from Canada, has been in stable condition since
April with a good quality of life.

"In my clinical experience patients with an advanced stage of brain tumor
after surgery should be given this therapy to prevent cancer recurrence,"
continues Dr. Li. "For glioma patients this comprehensive therapy can be a
real benefit and improve their life quality significantly."

Cellonis Biotechnologies focuses on R&D and the clinical application of
personalized stem cell therapies and immunotherapies for patients with
diseases including cancer, diabetes and central nervous system disorders.

    Urs. J. Lienert
    Email: ipsc@cellonis.com, urs.lienert@cellonis.com
    Web: www.cellonis.com,
         www.cellonis-anticancer.com (coming soon)

Urs. J. Lienert, COO-International, Cellonis, +86-150-1054-7487

will not be displayed